DMD drug launch going well, Sarepta CEO says; Street soundly agrees
SAN FRANCISCO – Concerns that launch expectations for Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) might be too ambitious were largely put to rest Tuesday, as CEO Ed Kaye provided updates on patient starts and reimbursement efforts and reported higher-than-expected fourth-quarter revenue.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST